Chiasma Supports Acromegaly Awareness Day
01 nov. 2019 08h00 HE
|
Chiasma, Inc.
WALTHAM, Mass., Nov. 01, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...
Chiasma to Report Third Quarter Financial Results on November 5, 2019
29 oct. 2019 08h00 HE
|
Chiasma, Inc.
WALTHAM, Mass., Oct. 29, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...
Chiasma to Present at the Cantor 2019 Global Healthcare Conference
25 sept. 2019 08h00 HE
|
Chiasma, Inc.
WALTHAM, Mass., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...
Chiasma Hosting Key Opinion Leader Meeting on Maintenance Therapy of Adult Patients with Acromegaly
05 sept. 2019 16h05 HE
|
Chiasma, Inc.
WALTHAM, Mass., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...
Chiasma to Present at the H.C. Wainwright 21st Annual Global Investment Conference
05 sept. 2019 08h00 HE
|
Chiasma, Inc.
WALTHAM, Mass., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...
Chiasma Reports Second Quarter 2019 Results
08 août 2019 16h05 HE
|
Chiasma, Inc.
Announces positive data from Phase 3 CHIASMA OPTIMAL trial; MYCAPSSA® NDA submission expected by year-end 2019 with an expected six-month PDUFA review time period MPOWERED enrollment complete;...
Chiasma to Report Second Quarter Financial Results on August 8, 2019
01 août 2019 16h05 HE
|
Chiasma, Inc.
WALTHAM, Mass., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...
Chiasma Announces Pricing of Underwritten Public Offering of $55.0 Million of Common Stock
26 juil. 2019 09h06 HE
|
Chiasma, Inc.
WALTHAM, Mass., July 26, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...
Chiasma Announces Proposed Offering of Common Stock
25 juil. 2019 16h01 HE
|
Chiasma, Inc.
WALTHAM, Mass., July 25, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...
Chiasma Announces Positive Phase 3 Top-Line Results from CHIASMA OPTIMAL Clinical Trial of Mycapssa® for the Maintenance Treatment of Adults with Acromegaly
23 juil. 2019 06h00 HE
|
Chiasma, Inc.
SPA-agreed trial met primary and all secondary endpoints No new or unexpected safety signals in the Mycapssa treated patients 90% of the patients treated with Mycapssa who completed the 36-week...